Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Related Videos

How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors? Video

How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?

How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?

How should we integrate and incorporate ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? When are these two tests potentially complementary? Video

How should we integrate and incorporate ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? When are these two tests potentially complementary?

Based on the evidence available, how should we be integrating and incorporating ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? In what settings, patients, and situations are these two tests potentially ...

What is your guidance about when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? How does this test compare to tissue-based NGS? Video

What is your guidance about when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? How does this test compare to tissue-based NGS?

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? And how does this test compare to tissue-based NGS? Which patients will benefit most?

Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling? Video

Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling?

Since assessing tumor mutational burden requires whole exome NGS profiling, and given the emerging pervasiveness of immunotherapy for many tumor types, how do you decide which tumor subtypes and patients, especially those with advanced ...

What are the actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data on tumor mutational burden, microsatellite instability (MSI), and related signatures? Video

What are the actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data on tumor mutational burden, microsatellite instability (MSI), and related signatures?

What are the current actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data related to tumor mutational burden, microsatellite instability (MSI), and related signatures?

What is the current and emerging role of liquid biopsies? Video

What is the current and emerging role of liquid biopsies?

What is the current and emerging role of liquid biopsies?

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable given what we know about genomically-targeted therapy? Video

Why are current genomic testing models based on targeted sequencing ("Hot Spot") unsustainable given what we know about genomically-targeted therapy?

Why are current genomic testing models based on targeted sequencing (“Hot Spot”) unsustainable given what we know about genomically-targeted therapy; and why have comprehensive genomic profiling (CGP) NGS platforms, such as those developed ...

Which of the four classes of genomic alterations--base substitutions, insertions and deletions, copy number alterations, and rearrangements--can a typical multi-gene "Hot Spot" test detect? Video

Which of the four classes of genomic alterations--base substitutions, insertions and deletions, copy number alterations, and rearrangements--can a typical multi-gene "Hot Spot" test detect?

Which of the four classes of genomic alterations—base substitutions, insertions and deletions, copy number alterations, and rearrangements can a typical multi-gene “Hot Spot” test detect? Which alterations does it fail to detect and why is NGS preferable?

What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer? Video

What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer?

What do the evolutionary studies of tumor progression—and heterogeneity—teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in patients with metastatic cancer?